Ieq Capital LLC Makes New Investment in Intellia Therapeutics, Inc. $NTLA

Ieq Capital LLC purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 49,375 shares of the company’s stock, valued at approximately $835,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NTLA. AQR Capital Management LLC lifted its holdings in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock valued at $646,000 after buying an additional 55,118 shares during the period. Woodline Partners LP purchased a new position in Intellia Therapeutics in the first quarter worth $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Intellia Therapeutics by 8.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock valued at $3,709,000 after acquiring an additional 38,521 shares during the period. Creative Planning lifted its holdings in Intellia Therapeutics by 12.9% in the second quarter. Creative Planning now owns 33,102 shares of the company’s stock valued at $310,000 after acquiring an additional 3,795 shares during the period. Finally, Cetera Investment Advisers boosted its position in shares of Intellia Therapeutics by 47.4% during the 2nd quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after purchasing an additional 10,785 shares in the last quarter. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Price Performance

Shares of NTLA opened at $13.11 on Friday. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of -3.90 and a beta of 1.81. The firm has a 50 day simple moving average of $13.31 and a 200-day simple moving average of $13.38.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.Intellia Therapeutics’s revenue was down 46.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.98) EPS. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -3.21 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on NTLA shares. Evercore upgraded shares of Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective for the company in a research note on Friday, August 7th. Citizens Jmp restated a “market outperform” rating and set a $30.00 target price on shares of Intellia Therapeutics in a research report on Tuesday. Wall Street Zen cut shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Wedbush lifted their price target on shares of Intellia Therapeutics from $12.00 to $17.00 and gave the company a “neutral” rating in a research report on Friday, July 10th. Finally, Wolfe Research lowered Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target on the stock. in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, eight have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $21.15.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,641 shares of Intellia Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the transaction, the executive vice president directly owned 156,286 shares of the company’s stock, valued at $2,813,148. The trade was a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is owned by company insiders.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.